
FBLG
Fibrobiologics Inc
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.340
Open
0.3264
VWAP
0.32
Vol
422.96K
Mkt Cap
19.32M
Low
0.305
Amount
135.86K
EV/EBITDA(TTM)
--
Total Shares
56.81M
EV
19.02M
EV/OCF(TTM)
--
P/S(TTM)
--
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
--
--
-0.080
-33.33%
--
--
-0.090
-35.71%
--
--
-0.070
-22.22%
Estimates Revision
The market is revising No Change the revenue expectations for FibroBiologics, Inc. (FBLG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -42.24%.
EPS Estimates for FY2025
Revise Upward

+3.33%
In Past 3 Month
Stock Price
Go Down

-42.24%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.340
Low
4.00
Averages
4.50
High
5.00
Current: 0.340
Low
4.00
Averages
4.50
High
5.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$10 -> $5
2025-11-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $5
2025-11-05
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on FibroBiologics to $5 from $10 and keeps a Buy rating on the shares. The firm adjusted the company's model to reflect an updated share count and tempered factor of patients receiving FibroBiologics' novel diabetic foot ulcer treatment pending further clinical validation.
H.C. Wainwright
Matthew Caufield
Buy
downgrade
$12 -> $10
2025-08-05
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$12 -> $10
2025-08-05
downgrade
Buy
Reason
H.C. Wainwright analyst Matthew Caufield lowered the firm's price target on FibroBiologics to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's progress continues across therapeutic fibroblast development.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-04-09
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-04-09
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-04-01
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$12
2025-04-01
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$12
2025-04-01
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-03-04
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-03-04
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Fibrobiologics Inc (FBLG.O) is -0.90, compared to its 5-year average forward P/E of -9.13. For a more detailed relative valuation and DCF analysis to assess Fibrobiologics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-9.13
Current PE
-0.90
Overvalued PE
0.78
Undervalued PE
-19.04
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q3
YoY :
+50.30%
-5.04M
Operating Profit
FY2025Q3
YoY :
+1055.60%
-5.78M
Net Income after Tax
FY2025Q3
YoY :
+1200.00%
-0.13
EPS - Diluted
FY2025Q3
YoY :
+52.01%
-3.98M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
16.8K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
16.8K
USD
Months
0-12
0
0.0
USD
Months
FBLG News & Events
Events Timeline
2025-11-20 (ET)
2025-11-20
08:07:19
FibroBiologics Secures HREC Approval for Phase 1/2 Trial of CYWC628
2025-10-31 (ET)
2025-10-31
16:32:21
FibroBiologics Announces Q3 Earnings Per Share of 13 Cents, Exceeding Two Estimates of 12 Cents
2025-09-11 (ET)
2025-09-11
08:33:03
FibroBiologics Reveals IND-Enabling Progress in Psoriasis Research Program
Sign Up For More Events
Sign Up For More Events
News
8.5
11-20Yahoo FinancePinnedFibroBiologics Completes $4 Million Registered Direct Offering Priced According to Nasdaq Regulations
4.5
11-21TipRanksVTI ETF Daily Report — November 21, 2025
4.5
11-20TipRanksVTI ETF Daily Update - November 20, 2025
Sign Up For More News
People Also Watch

NVA
Nova Minerals Ltd
7.970
USD
+2.57%

APT
Alpha Pro Tech Ltd
4.610
USD
+1.10%

VRCA
Verrica Pharmaceuticals Inc
4.210
USD
+4.73%

SRFM
Surf Air Mobility Inc
2.070
USD
+0.49%

WAI
Top KingWin Ltd
2.460
USD
-10.22%

IPWR
Ideal Power Inc
3.600
USD
-2.70%

NIXX
Nixxy Inc
1.100
USD
-0.90%

WAVE
Eco Wave Power Global AB (publ)
6.770
USD
-5.45%

RVPH
Reviva Pharmaceuticals Holdings Inc
0.512
USD
+6.67%
FAQ
What is Fibrobiologics Inc (FBLG) stock price today?
The current price of FBLG is 0.34 USD — it has increased 4.62 % in the last trading day.





